FDA Preparing Guidance on Compounding Pandemic Drugs

The FDA announced that it is developing guidance on compounding drugs during the COVID-19 pandemic to protect patients from “unsafe, ineffective and poor-quality compounded drugs, while preserving access for patients.”
Source: Drug GMP Report